| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
| 23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
| 22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
| 16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 05 Apr 2022 | Liquidity and counterparty agreements | The Company communicates that it has entered into a liquidity agreement with Bestinver S.V., S.A. | Download |
| 29 Mar 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted on 28 March 2022 and end of the share buyback program | Download |
| 28 Mar 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 21 March 2022 and 25 March 2022 | Download |
| 21 Mar 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 March 2022 and 18 March 2022 | Download |
| 14 Mar 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 March 2022 and 11 March 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
| 26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
| 15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
| 09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
| 08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |